News

Latest Industry Updates

From company milestones to industry breakthroughs, uncover the stories making waves and shaping the narrative in real time.

CluePoints Announced as Fierce Life Sciences Innovation Awards Finalist
RBQM leader secures finalist position in the Data Analytics/Business Intelligence category at prestigious...
Read
Continuous Review Needs Consolidated Evidence and Fewer Dashboards
Continuous data review calls for fewer dashboards and one body of consolidated evidence, built with RBQM...
Read
CluePoints Shortlisted for 2026 Scrip Awards for the Third Time in Eight Years
Clinical Trial Vanguard covers CluePoints’ 2026 Scrip Awards shortlisting and what it signals about data...
Read
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD discuss what...
Read
Why Time Savings Is the Largest Driver of RBQM's Financial Value
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain why...
Read
Why Quantifying the Financial Value of RBQM Has Been So Hard- and What This Study Did Differently
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how...
Read
1 2 3 … 36
CluePoints Announced as Fierce Life Sciences Innovation Awards Finalist

RBQM leader secures finalist position in the Data Analytics/Business Intelligence category at prestigious awards. WAYNE, PA...

Continuous Review Needs Consolidated Evidence and Fewer Dashboards

Continuous data review calls for fewer dashboards and one body of consolidated evidence, built with RBQM...

Source: Contract Pharma

CluePoints Shortlisted for 2026 Scrip Awards for the Third Time in Eight Years

Clinical Trial Vanguard covers CluePoints’ 2026 Scrip Awards shortlisting and what it signals about data oversight...

Source: The Clinical Trial Vanguard

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD discuss...

Source: Tufts Center for the Study of Drug Development

Why Time Savings Is the Largest Driver of RBQM’s Financial Value

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain...

Source: Applied Clinical Trials

Why Quantifying the Financial Value of RBQM Has Been So Hard- and What This Study Did Differently

In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain...

Source: Applied Clinical Trials

CluePoints Shortlisted for 2026 Scrip Awards Following 2023 and 2025 Wins

The two-time category winner secures finalist position in the Best Contract Research Organization (Specialist Providers) category....

Trial Complexity is the New Normal

Clinical trial complexity is now the norm: more endpoints, more procedures, narrower eligibility criteria, and more...

Source: pharmaphorum

CluePoints Launches Three AI-Led Clinical Data Review Capabilities, Co-Innovated with a Top 10 Pharmaceutical Company

Intelligent Query Detection, Medical & Safety Review and Intelligent Medical Coding are now generally available, extending...

Making the Financial Case for Risk-Based Quality Management in Clinical Research- Q&A

New peer-reviewed research puts hard numbers to the financial value of RBQM, showing ROI multiples up...

Source: The Association of Clinical Research Professionals

The CRA of the Future

Clinical research associates are evolving from compliance-focused manual monitors to data-enabled strategic site partners, but organizations...

Source: Applied Clinical Trials

Applying Risk-Based Oversight to Ensure Real-World Data Integrity

Clinical trials have undergone a period of immense change. Use of real-world data (RWD) is increasing....

Source: PharmaLive

CluePoints Introduces Data Quality Oversight Service For Site Inspection Readiness

Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Centralized Statistical Monitoring (CSM)...

FDA Signs Agreement With CluePoints To Explore A Data-Driven Approach To Quality Oversight In Clinical Trials

Cambridge, MA – FDA and its stakeholders have an interest in assuring the integrity of clinical...

CluePoints Teams Up With Paragon Solutions To Share The Secrets Of Successful Risk-Based Monitoring Implementation

We’re delighted to announce that are our next Risk-Based Monitoring implementation webinar is open for registration!...

CluePoints Announces Locations For Risk-Based Monitoring Implementation Roadshows

The CluePoints and OmniComm Risk-Based Monitoring Implementation Roadshow is Coming to a City Near You! In...

CluePoints Announces Free Risk-Based Monitoring Strategy Review

We’re thrilled to announce that CluePoints is now offering a complimentary Risk-Based Monitoring strategy Check-up and...

CluePoints Appoints Steve Young As Senior Vice President Of US Operations

Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) and Data Quality Oversight solutions...

CluePoints CEO, François Torche, Honored In PharmaVOICE 100

Cambridge, MA – CluePoints, a leading provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has...

CluePoints Risk-Based Monitoring Platform (Version 1.9.0) Is Live!

We’re thrilled to announce that CluePoints’ latest version (1.9.0) of the Central Monitoring platform is live!...

CluePoints Founder, Marc Buyse To Deliver Clinical Trial Data Quality Course At The ASA Biopharmaceutical Workshop

The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop is fast approaching and we’re thrilled to announce that...

Unveiling CluePoints’ New And Improved Risk-Based Monitoring Software

Today, we’re thrilled to unveil CluePoints’ latest release of its award-winning Risk-Based Monitoring Software. For this...

CluePoints Announce 2nd Annual Risk-Based Monitoring Roadshows To Take Place In Basel, Switzerland & Cambridge, UK

Join CluePoints CEO Francois Torche and OmniComm Sr. Director Steve Young at this special thought leadership...

CluePoints Named Clinical Research & Excellence Awards Finalist

Awards recognize CluePoints’ Risk-Based Monitoring solution in the ‘Best Sponsor-Focused Technological Development’ category. Cambridge, MA –...

Central Monitoring Use in Early-Phase and Small Enrollment Trials

Central monitoring is highly effective in detecting emerging quality issues in clinical trials, but debate continues...

Source: Applied Clinical Trials

Risk Planning: A Review of Industry Trends

An essential component of risk-based quality management (RBQM), as detailed in both the ICH E8 (R1)...

Source: Applied Clinical Trials

Achieving Optimal Adoption of Risk-Based Quality Management

The need to boost education, shift culture, and embrace new technologies.

...

Source: Applied Clinical Trials

The Negative Impact of Failing to Implement Risk-Based Quality Management

As an industry, we regularly discuss the benefits of adopting risk-based quality management (RBQM). The good...

Source: International Clinical Trials/European Pharmaceutical Contractors

There’s No Such Thing as Too Much Data

François Torche dispels the myth that, at least in RBQM, there is such a thing as...

Source: PM360

Using RBQM and New Technologies to Enhance Data Analysis and Enable Faster Review and Decision Making

An increase in clinical trial data is driving demand for enhanced clinical trial processes. Sponsors want...

Source: Journal for Clinical Studies

Advancing Technology in Clinical Trials

With increasing pressure to overcome drug development challenges and advance drugs to market faster and with...

Source: Contract Pharma

CRO Industry Report

Today’s drug development landscape demands contract research organizations (CROs) provide flexible models that leverage the latest...

Source: Contract Pharma

DIA 2024: Pat Hughes of CluePoints Highlights Renewed Agreement With FDA, Utilizing AI in RBQM

In an interview with ACT editor Andy Studna at DIA 2024, Hughes, co-founder and chief commercial...

Source: Applied Clinical Trials

Does Risk-Based Quality Management (RBQM) Actually Improve Quality?

Over the past 10 years we have seen a lot of progress in risk-based quality management...

Source: ACRP

Quality Tolerance Limits: An Updated View of Industry Trends

We presented an initial review of quality tolerance limit (QTL) adoption trends in the March 2023...

Source: Applied Clinical Trials

FDA and CluePoints Extend Existing Collaboration to Include AI/ML for Quality Assessment

Under the new extension, FDA and CluePoints will enhance CluePoints’ SMART software to address a broader...

Source: Applied Clinical Trials